Cesare Gridelli, MD, is the Chief of the Division of Medical Oncology at “S.G. Moscati” Hospital, Avellino (Italy) and Director of the Department of Oncology/Hematology at the same institution. His areas of expertise are lung cancer and cancer in the elderly. He is deeply involved in the clinical development of new anticancer-targeted therapies and immunotherapy. He is a member of several national and international scientific societies. He served as President of the Italian Association of Thoracic Oncology (AIOT) from 2013 to 2017. He is a member of the Advisory Board of scientific journals and of several expert panels. He has been invited as a speaker at international conferences and educational activities of oncology societies (ASCO, ESMO, etc.). He gave three oral presentations on clinical trials and five educational talks at the annual ASCO meetings. He received the Awards and Lecture in Geriatric Oncology of the American Society of Medical Oncology (ASCO) in 2021. He is the author of about 500 extended papers published in international indexed journals and several chapters of books. His papers have about 22,000 citations in international indexed journals. Dr. Gridelli has an h-index Scopus of 68. In November 2013, the American agency Expertscape (Palo Alto, California) appointed Dr. Gridelli in first place among the top world experts on lung cancer. His first place position was confirmed by the same American agency in August 2019.
Diego Luigi Cortinovis, MD, since 2008, has been Vice-Director of the oncology unit at San Gerardo Hospital in Monza, Italy, part of the University of Milan Bicocca. Since October 2023, he has been the Chief of Medical Oncology at Fondazione IRCCS San Gerardo dei Tintori Monza and Associate Professor of Medical Oncology at Università degli Studi Milano-Bicocca. His research interests include thoracic malignancies, lung cancer, mesothelioma, and esophagus cancer. He has been a Principal Investigator and Co-Investigator in different clinical trials since 2003. His primary interests are targeted therapies in non-small-cell lung cancer, new approaches in small-cell lung cancer and modern therapies in malignant pleural mesothelioma, as well as translational research related to predictive biomarkers. He has been involved in different key trials investigating new approaches in the treatment of advanced stages of disease like maintenance therapy or treatment with targeted therapies as well as key biomarker trials. He is a co-author in many scientific papers, peer-reviewed journals, and a member of scientific journal boards. He is a member of different scientific societies including ESMO, IASLC, and AIOM.
Paolo Bironzo practices in Orbassano, Italy. He is Assistant Professor at University of Turin, Department of Oncology. His top areas of expertise are lung cancer, mesothelioma, non-small-cell lung cancer (NSCLC), and small-cell lung cancer (SCLC). His clinical research consists of co-authoring 90 peer-reviewed articles in the past 15 years.
Alessandra Bearz practices in Aviano, Italy, where she is responsible of the Lung and pleural tumor Division, and Director of Phase I trial Program. Her top areas of expertise are lung cancer, non-small-cell lung cancer (NSCLC), and pleural neoplasms. She is involved in clinical trials and published more than 100 peer-reviewed articles.
Filippo De Marinis is an expert in clinical trials in the thoracic oncology field. He actively took part in the decision-making process of all the international clinical trials with new drugs that were successfully approved for use in clinical practice in Italy and in other European countries. He works at the European Institute of Oncology in Milan as chair of the new Division of Thoracic Oncology, part of the integrated Lung Cancer Program, dedicated to prevention, diagnosis, care, and clinical research for patients with lung cancers (but also for patients affected by thymic, mediastinal, and pleural cancer ). He is a member of the Scientific Italian and International Associations with active roles. Among others, he was a founding member and president of AIOT (Italian Thoracic Oncology Association); regional and national counselor of AIOM (Italian Medical Oncology Association); and a member of ESMO (European Society of Medical Oncology), ASCO (American Society of Clinical Oncology), IASLC (International Association for the Study of Lung Cancer), and ETOP (European Thoracic Oncology Platform). As a Key Opinion Leader in lung cancer, he has been invited as speaker/chair to more than 300 national and international congresses in the last 5 years, and he is also the author of more than 250 publications in 130 different, indexed, peer-reviewed scientific journals.
